[Translation] A phase 1 study of bemarituzumab combined with mFOLFOX6 and nivolumab in Chinese subjects with advanced gastric or gastroesophageal junction cancer and FGFR2b overexpression
主要目的:表征 bemarituzumab 的 PK 特征。
次要目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的安全性和耐受性。评价 bemarituzumab 的 ADA。
探索性目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的疗效。
[Translation] Primary objective: Characterize the PK characteristics of bemarituzumab.
Secondary objectives: Evaluate the safety and tolerability of bemarituzumab+mFOLFOX6 and nivolumab. Evaluate the ADA of bemarituzumab.
Exploratory objectives: Evaluate the efficacy of bemarituzumab+mFOLFOX6 and nivolumab.